Cambridge Investment Research Advisors, Inc. Immatics N.V. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2023 Jul 13, 2023	BUY	$5.92 - $12.72 $2,072 - $4,452	350 Added 2.44%	14,717 $170,000
Q1 2023 May 11, 2023	BUY	$6.74 - $9.44 $96,833 - $135,624	14,367 New	14,367 $99,000

Others Institutions Holding IMTX

# of Institutions

101

Shares Held

75.8M

Call Options Held

238K

Put Options Held

727K

Rtw Investments, LP New York, NY

10M
Shares

$81.7 Million
1.82% of portfolio
Wellington Management Group LLP Boston, MA

9.68M
Shares

$79.1 Million
0.02% of portfolio
Perceptive Advisors LLC New York, NY

8.09M
Shares

$66.1 Million
2.41% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

7.38M
Shares

$60.3 Million
0.05% of portfolio
Baker Bros. Advisors LP New York, NY

6.44M
Shares

$52.6 Million
0.79% of portfolio

View Full List

About Immatics N.V.

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $623M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

More about IMTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account